Last reviewed 2026-05-15 · How we verify

Abdominal wall block with liposomal bupivicaine

University of California, Los Angeles · FDA-approved active Small molecule Quality 0/100

Abdominal wall block with liposomal bupivicaine is a Small molecule drug developed by University of California, Los Angeles. It is currently FDA-approved. Also known as: Exparel.

At a glance

Generic name	Abdominal wall block with liposomal bupivicaine
Also known as	Exparel
Sponsor	University of California, Los Angeles
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Abdominal wall block with liposomal bupivicaine CI brief — competitive landscape report
Abdominal wall block with liposomal bupivicaine updates RSS · CI watch RSS
University of California, Los Angeles portfolio CI

Frequently asked questions about Abdominal wall block with liposomal bupivicaine

What is Abdominal wall block with liposomal bupivicaine?

Abdominal wall block with liposomal bupivicaine is a Small molecule drug developed by University of California, Los Angeles.

Who makes Abdominal wall block with liposomal bupivicaine?

Abdominal wall block with liposomal bupivicaine is developed and marketed by University of California, Los Angeles (see full University of California, Los Angeles pipeline at /company/university-of-california-los-angeles).

Is Abdominal wall block with liposomal bupivicaine also known as anything else?

Abdominal wall block with liposomal bupivicaine is also known as Exparel.

What development phase is Abdominal wall block with liposomal bupivicaine in?

Abdominal wall block with liposomal bupivicaine is FDA-approved (marketed).

Manufacturer: University of California, Los Angeles — full pipeline
Also known as: Exparel
Compare: Abdominal wall block with liposomal bupivicaine vs similar drugs
Pricing: Abdominal wall block with liposomal bupivicaine cost, discount & access